Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing Gn protects mice against rift valley fever virus

PLoS Neglected Tropical Diseases

Volumn 4, Issue 6, 2010, Pages

  Bhardwaj, Nitin ^a,b   Heise, Mark T ^d   Ross, Ted M ^b,c  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3D; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; INACTIVATED VIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA; PLASMID VECTOR; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VECTOR; DNA VACCINE; IMMUNOGLOBULIN CLASS; PEPTIDE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELL LINE; CELL STIMULATION; CELLULAR IMMUNITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DNA IMMUNIZATION; DNA VECTOR; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; EMBRYO; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INCUBATION TIME; INFECTION PREVENTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; REPLICON; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; SINGLE DRUG DOSE; VIRAL GENE DELIVERY SYSTEM; VIRUS EXPRESSION; VIRUS VIRULENCE; ALPHA VIRUS; ANALYSIS OF VARIANCE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; PASSIVE IMMUNIZATION; PLASMID; WEIGHT REDUCTION;

ALPHAVIRUS; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; COMPLEMENT C3D; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN ISOTYPES; MICE; MICE, INBRED BALB C; PEPTIDES; PLASMIDS; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; WEIGHT LOSS;

EID: 77956999261     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000725     Document Type: Article

References (55)

1. Daubney RJ, Hudson JR, Garnham PC (1931) Enzootic hepatitis of Rift Valley fever: an undescribed virus disease of sheep, cattle and man from East Africa. J Pathol Bacteriol 34: 543-579.
2. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, et al. (2003) Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 37: 1084-1092.
3. Meegan J (1981) Rift Valley fever in humans in Egypt: an overview of epizootics in 1977 and 1978. Contrib Epidemiol Biostat 3: 100-113.
4. Jouan A, Coulibaly I, Adam F, Philippe B, Riou O, et al. (1989) Analytical study of a Rift Valley fever epidemic. Res Virol 140: 175-186.
5. Shoemaker T, Boulianne C, Vincent MJ, Pezzanite L, Al-Qahtani MM, et al. (2002) Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01. Emerg Infect Dis 8: 1415-1420.
6. Nguku P, Sharif S, Omar A, Nzioka C, Muthoka P, et al. (2007) Rift Valley fever outbreak-Kenya, November 2006-January 2007. MMWR Morb Mortal Wkly Rep 56: 73-76.
7. Schmaljohn CS, Hooper JW (2001) Bunyaviridae: The viruses and their replication. Fields' Virology. Philadelphia: Lippincott Williams & Wilkins.
8. Gerrard SR, Nichol ST (2007) Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology 357: 124-133.
9. Gerrard SR, Bird BH, Albarino CG, Nichol ST (2007) The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection. Virology 359: 459-465.
10. Vialat P, Billecocq A, Kohl A, Bouloy M (2000) The S segment of rift valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice. J Virol 74: 1538-1543.
11. Won S, Ikegami T, Peters CJ, Makino S (2007) NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J Virol 81: 13335-13345.
12. Lim DV, Simpson JM, Kearns EA, Kramer MF (2005) Current and developing technologies for monitoring agents of bioterrorism and biowarfare. Clin Microbiol Rev 18: 583-607.
13. Pittman P, Liu C, Cannon T, Makuch R, Mangiafico J, et al. (1999) Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12- year experience. Vaccine 18: 181-189.
14. Meadors GF, 3rd, Gibbs PH, Peters CJ (1986) Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials. Vaccine 4: 179-184.
15. Kamal SA (2009) Pathological studies on postvaccinal reactions of Rift Valley fever in goats. Virol J 6: 94.
16. Botros B, Omar A, Elian K, Mohamed G, Soliman A, et al. (2006) Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol 78: 787-791.
17. Caplen H, Peters CJ, Bishop DH (1985) Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66(Pt 10): 2271-2277.
18. Hunter P, Erasmus BJ, Vorster JH (2002) Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J Vet Res 69: 95-98.
19. Mkrtichyan M, Ghochikyan A, Movsesyan N, Karapetyan A, Begoyan G, et al. (2008) Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization. DNA Cell Biol 27: 19-24.
20. Bower JF, Sanders KL, Ross TM (2005) C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences. Curr HIV Res 3: 191-198.
21. Watanabe I, Ross TM, Tamura S, Ichinohe T, Ito S, et al. (2003) Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin. Vaccine 21: 4532-4538.
22. Mitchell JA, Green TD, Bright RA, Ross TM (2003) Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin- C3d fusion proteins. Vaccine 21: 902-914.
23. Green TD, Montefiori DC, Ross TM (2003) Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 77: 2046-2055.
24. Ross TM, Xu Y, Green TD, Montefiori DC, Robinson HL (2001) Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses 17: 829-835.
25. Ross TM, Xu Y, Bright RA, Robinson HL (2000) C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 1: 127-131.
26. Toapanta FR, Ross TM (2006) Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol Res 36: 197-210.
27. Pushko P, Geisbert J, Parker M, Jahrling P, Smith J (2001) Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 75: 11677-11685.
28. Gorchakov R, Volkova E, Yun N, Petrakova O, Linde N, et al. (2007) Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins. Virology 366: 212-225.
29. Heise MT, Whitmore A, Thompson J, Parsons M, Grobbelaar AA, et al. (2009) An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus. Epidemiol Infect 137: 1309-1318.
30. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT (1996) C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271: 348-350.
31. Balasuriya UB, Heidner HW, Davis NL, Wagner HM, Hullinger PJ, et al. (2002) Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 20: 1609-1617.
32. Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DH, et al. (1995) Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 13: 1427-1430.
33. Haynes JR, Fuller DH, Eisenbraun MD, Ford MJ, Pertmer TM (1994) Accell particle-mediated DNA immunization elicits humoral, cytotoxic, and protective immune responses. AIDS Res Hum Retroviruses 10 Suppl 2: S43-45.
34. Pertmer TM, Robinson HL (1999) Studies on antibody responses following neonatal immunization with influenza hemagglutinin DNA or protein. Virology 257: 406-414.
35. Bower JF, Ross TM (2006) A minimum CR2 binding domain of C3d enhances immunity following vaccination. Advances in experimental medicine and biology 587: 249-264.
36. Pittman PR, Liu CT, Cannon TL, Makuch RS, Mangiafico JA, et al. (1999) Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 18: 181-189.
37. Toapanta FR, Ross TM (2009) Impaired immune responses in the lungs of aged mice following influenza infection. Respir Res 10: 112.
38. Wallace DB, Ellis CE, Espach A, Smith SJ, Greyling RR, et al. (2006) Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 24: 7181-7189.
39. Spik K, Shurtleff A, McElroy AK, Guttieri MC, Hooper JW, et al. (2006) Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tickborne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24: 4657-4666.
40. Schmaljohn CS, Parker MD, Ennis WH, Dalrymple JM, Collett MS, et al. (1989) Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 170: 184-192.
41. Lagerqvist N, Naslund J, Lundkvist A, Bouloy M, Ahlm C, et al. (2009) Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virol J 6: 6.
42. Gorchakov R, Volkova E, Yun N, Petrakova O, Linde NS, et al. (2007) Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins. Virology 366: 212-225.
43. Naslund J, Lagerqvist N, Habjan M, Lundkvist A, Evander M, et al. (2009) Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 385: 409-415.
44. Randall R, Binn LN, Harrison VR (1964) Immunization against Rift Valley Fever Virus. Studies on the Immunogenicity of Lyophilized Formalin- Inactivated Vaccine. J Immunol 93: 293-299.
45. Hubbard KA, Baskerville A, Stephenson JR (1991) Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever. Am J Vet Res 52: 50-55.
46. Lubroth J, Rweyemamu MM, Viljoen G, Diallo A, Dungu B, et al. (2007) Veterinary vaccines and their use in developing countries. Rev Sci Tech 26: 179-201.
47. van Oirschot JT (1999) Diva vaccines that reduce virus transmission. J Biotechnol 73: 195-205.
48. Bird BH, Albarino CG, Hartman AL, Erickson BR, Ksiazek TG, et al. (2008) Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 82: 2681-2691.
49. Jansen van Vuren P, Potgieter AC, Paweska JT, van Dijk AA (2007) Preparation and evaluation of a recombinant Rift Valley fever virus N protein for the detection of IgG and IgM antibodies in humans and animals by indirect ELISA. J Virol Methods 140: 106-114.
50. Naslund J, Lagerqvist N, Lundkvist A, Evander M, Ahlm C, et al. (2008) Kinetics of Rift Valley Fever Virus in experimentally infected mice using quantitative real-time RT-PCR. J Virol Methods 151: 277-282.
51. Zaki A, Coudrier D, Yousef AI, Fakeeh M, Bouloy M, et al. (2006) Production of monoclonal antibodies against Rift Valley fever virus Application for rapid diagnosis tests (virus detection and ELISA) in human sera. J Virol Methods 131: 34-40.
52. Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9: 776-788.
53. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, et al. (2007) Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25: 2120-2127.
54. Keegan K, Collett MS (1986) Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus. J Virol 58: 263-270.
55. Lorenzo G, Martin-Folgar R, Rodriguez F, Brun A (2008) Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. Vaccine 26: 5255-5262.